Anaphylaxis News and Research

RSS
Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Children with asthma have higher risk of obesity

Children with asthma have higher risk of obesity

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Kids with mild or moderate adverse events following immunization can be safely reimmunized

Kids with mild or moderate adverse events following immunization can be safely reimmunized

Researchers develop new DNA-based test to detect trace amounts of peanuts in foods

Researchers develop new DNA-based test to detect trace amounts of peanuts in foods

Chigger bites may trigger allergic reaction to red meat

Chigger bites may trigger allergic reaction to red meat

FDA grants approval for first generic version of epinephrine auto-injector

FDA grants approval for first generic version of epinephrine auto-injector

Saving sight of millions by making eye injections safe and comfortable

Saving sight of millions by making eye injections safe and comfortable

Study finds tick bite meat allergy as most common cause of anaphylaxis

Study finds tick bite meat allergy as most common cause of anaphylaxis

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Infants have less severe food-induced anaphylaxis unlike older children

Infants have less severe food-induced anaphylaxis unlike older children